CEBPB and cholangiocarcinoma: However, the clinical database indicated no significant difference in sorafenib sensitivity between high-CEBPB and low-CEBPB groups of pancreatic cancer (Supplementary Fig. S8D) and cholangiocarcinoma (Supplementary Fig. S12C).